Cargando…
Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy (EMERALD)
INTRODUCTION: Diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR) are the major causes of sight loss in people with diabetes. Due to the increased prevalence of diabetes, the workload related to these complications is increasing making it difficult for Hospital Eye Services (H...
Autores principales: | Lois, Noemi, Cook, Jonathan, Aldington, Stephen, Waugh, Norman, Mistry, Hema, Sones, William, McAuley, Danny, Aslam, Tariq, Bailey, Claire, Chong, Victor, Ghanchi, Faruque, Scanlon, Peter, Sivaprasad, Sobha, Steel, David, Styles, Caroline, McNally, Christine, Rice, Rachael, Prior, Lindsay, Azuara-Blanco, Augusto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609061/ https://www.ncbi.nlm.nih.gov/pubmed/31256030 http://dx.doi.org/10.1136/bmjopen-2018-027795 |
Ejemplares similares
-
Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy: The EMERALD Study
por: Lois, Noemi, et al.
Publicado: (2021) -
Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study
por: Maredza, Mandy, et al.
Publicado: (2022) -
Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial
por: Lois, Noemi, et al.
Publicado: (2019) -
Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023) -
Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2021)